GO
Loading...

Express Scripts Holding Co

More

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Cramer's guide to a treacherous trader's market Tuesday, 13 Jan 2015 | 6:14 PM ET

    One minute it's up, the next minute it's down. Jim Cramer gives two important tips for navigating the rough seas of a volatile market.

  • Jan 8- Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the...

  • Jan 8- AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. U.S. health regulators approved Viekira Pak, AbbVie's all-oral treatment for hepatitis C in December. AbbVie's newly approved regimen is also cheaper than Gilead's...

  • Jan 5- CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception. The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows...

  • Gilead fights back: CVS deal sends shares soaring Monday, 5 Jan 2015 | 1:05 PM ET
    Pedestrians walk by a CVS store in San Francisco.

    Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.

  • Drug pricing concerns? Not at Gilead Monday, 5 Jan 2015 | 10:41 AM ET
    A scientist at Gilead Sciences' laboratory in Foster City, Calif.

    Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.

  • FDA approves 41 novel medicines in 2014 vs 27 in 2013. LONDON, Jan 1- U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines in...

  • It was a year when Cynk Technology, a development-stage company with no revenue, was briefly worth $6 billion, and when a long-forgotten closed-end fund focused on Cuba- the Herzfeld Caribbean Basin Fund- saw more trading in one day in December than it had in six years. With a current market value of about $663 billion, if one were to pick a company that would be the...

  • After-hours buzz: Cal-Maine Foods, Gilead & Sony Tuesday, 23 Dec 2014 | 5:00 PM ET

    Check out which companies are making headlines after the bell Tuesday: Cal-Maine Foods, Gilead & Sony.

  • *Dow, S&P rise for 5th day, both end at records. NEW YORK, Dec 23- U.S. stocks rose on Tuesday, with the Dow closing above 18,000 for the first time ever and the S&P 500 ending at a record after an unexpectedly strong report on economic growth. The Dow rose as high as 18,069.22 and is up about 175 percent from a 12- year closing low hit on March 9, 2009.

  • Record-setting day: Dow's first finish above 18,000 Tuesday, 23 Dec 2014 | 4:06 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Stocks furthered record gains Tuesday after the economy expanding in the third quarter by the most in 11 years.

  • NEW YORK, Dec 23- U.S. stocks rose for a fifth straight session on Tuesday, with the Dow climbing above 18,000 for the first time ever after an unexpectedly strong report on economic growth. Both the Dow and S&P 500 hit intraday records, and the S&P is on track for its 51st record close of 2014. The gains pushed the Dow as high as 18,051.14, and the blue-chip index is now up...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • HALFTIME REPORT FINAL TRADES Tuesday, 23 Dec 2014 | 1:00 PM ET

    Halftime Report traders give their final trades for the day.

  • NEW YORK, Dec 23- U.S. stock index futures were little changed on Tuesday, after the Dow and S&P 500 closed at fresh records and ahead of a raft of economic data. *Major Wall Street indexes have risen for four straight sessions, pushing the benchmark S&P index to its 50th record high of the year. The S&P has risen 5.4 percent over that period, its best 4- day run since July...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • *Gilead falls as Express Scripts picks AbbVie treatment. *Dow boosted by gains at Intel, IBM; Dow, S&P end at record. Intel Corp rose 2.3 percent to $37.21, providing the biggest boost to the Dow, while IBM rose 1.8 percent to $161.44 and Cisco Systems rose 1.6 percent to $28.22.